Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Tissue Factor

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101878

Synonyms

Historical Background

Morawitz was the first to describe the clot-promoting substance found in tissues (tissue factor) and introduced it into his clotting theory. He proposed a clotting theory which influenced research in this field over the next 50 years.

Until 1962 12 main clotting factors were described, but their interrelationship was unknown. In 1964, Davie and Macfarlane independently formulated the “cascade theory” of in vivo clotting. Only 30 years later, in 1995, Rapaport and Rao were able to write “Thus little reason exists today to doubt that the binding of factor VII to TF and the subsequent reactions so triggered play a ‘prima ballerina’ role in the initiation of coagulation process.”

In 1987, the efficiency of purification of human tissue factor (TF) from brain and placenta was greatly improved by using a monoclonal antibody against human tissue factor on immunoadsorbent columns. Monoclonal antibodies against human tissue factor allowed immunohistochemical localization of tissue factor in different organs and tissues for the first time. The next step was to isolate the tissue factor gene. Four different groups published the cDNA sequence of the tissue factor gene and its 50 and 30 flanking sequences concurrently in 1987 (Fisher et al. 1987; Morrissey et al. 1987; Scarpati et al. 1987; Spicer et al. 1987).

Cellular and molecular mechanisms underlying tissue factor function are pluripotential. But there is no doubt that tissue factor is the key element of initiation of external coagulation pathway and seems to be the leading factor of trombogenicity of atherosclerotic plaque.

Tissue factor is also unique in that no congenital deficiency of this factor has been established. In the mouse embryo, tissue factor deficiency led to fetal death signifying its importance in maintaining life.

Tissue Factor Structure

Tissue factor is a transmembrane glycoprotein with the molecular weight of 47 kD which is fixed in the form of alpha-helix to a cell membrane. This protein consists of three domains and 263/261 amino acids (Butenas et al. 2009).
  1. 1.

    Extracellular domain is presented by NH2-terminal molecular part (amino acid residues from 1 to 219) and is made up of two fibronectin molecules of type III. There are three potential N-terminal binding areas with carbohydrates (Muller et al. 1994).

     
  2. 2.

    Transmembrane hydrophobic domain by which tissue factor is fixed to the membrane (amino acid residues from 220 to 242).

     
  3. 3.

    Cytoplasmic COOH-terminal domain.

     

Amino acid sequences transcribed from nucleotide sequences of human placental DNA code have shown that tissue factor derives from a larger precursor molecule. The latter has an additional sequence of 32 amino acids (Spicer et al. 1987).

Extracellular and transmembrane domains of tissue factor play an essential role in hemocoagulation (Muller et al. 1994; Edgington 1991). Cytoplasmic domain is significant in signal transduction. It is considered that tissue factor without cytoplasmic domain is functionally totally identical to the initiating thrombin generation protein. In addition, recombinant tissue factor deprived of both transmembrane and cytoplasmic domains is unable to fix to the cell membrane. It cannot activate factor VII and has decreased catalytic efficiency in relation to factor IX and factor X, although it can form a complex with factor VIIa (Fiore et al. 1994).

Regulation Mechanisms of Tissue Factor Expression

Tissue factor expression is principally regulated at the translation level (Mackman 1997). Promotor element of human tissue factor contains five binding sites with the specific protein-1 (Sp1), three binding sites with epidermal growth factor-1 (Egr-1), two binding sites with activator protein 1 (AP-1), and one binding site with nuclear factor kappa B (NF-κB). It is considered that Sp1 sites are mainly responsible for stable expression of tissue factor basal level. Sites Egr-1, AP-1, and NF-κB are primarily responsible for induced expression of tissue factor (Ruf et al. 1991; Mackman 1997). Many cells can produce TF when they are stimulated in vitro by various agents. It is known that tissue factor expression in endothelial cells and in monocytes/macrophages can be induced by tumor necrosis factor-alpha (TNFa), interleukin-1β, ligand CD40, bacterial lipopolysaccharide (LPS), vascular endothelial growth factor, oxidated and acetylated low-density lipoproteins (oxLDL), hypoxia, and hemodynamic stress (Mackman 2004). Aberrant expression of tissue factor can lead to fatal consequences as seen with sepsis, malignancy, and atherosclerosis.

It has been proposed that encryption is the posttranslational suppression of TF procoagulant activity (PCA) on the cell surface. Encrypted TF in normal blood is associated with monocytes and platelets. Tissue factor (TF) procoagulant activity (PCA) is not fully expressed in an otherwise normal unperturbed cell. Lipid raft association may also contribute to TF encryption.

An increase in cytosolic calcium can lead to the decryption of TF PCA. The final step in the decryption of TF PCA is the activation of zymogen factor VII.

Tissue factor differs from other cofactors of hemocoagulation cascade which circulate in inactive state. Tissue factor expressed on the cell surface is functionally active. Tissue factor is present in subendothelial tissue, in thrombocytes and leukocytes, in vascular adventitia, in astrogliocytes and in visceral capsules and is found in relatively high concentration in central nervous system, in lungs, in myocardium (Mackman and Parker 2014) and in placenta (Eddleston et al. 1993; Butenas et al. 2009).

It has been established that tissue factor plays the leading role in pathogenesis of vascular diseases, systemic inflammation, and hemocoagulation. It is significant in cross inflammation processes and coagulation (Mackman 2004; Piazza and Ridker 2015). Tissue factor can bind with cell receptors, where, in its turn, it contributes to the production and release of inflammatory mediators. It has been shown that monocytes and macrophages express tissue factor after cytokine stimulation (Bouchard et al. 2003).

The Role of Tissue Factor in Hemocoagulation

Tissue factor is necessary for the conversion of prothrombin into thrombin (Mackman 2004). In extrinsic coagulation pathway tissue factor activates factor VII (Mariani et al. 1999). Activated factor VII, in its turn, activates coagulation factors IX and X. Activated factor X in the presence of factor V, calcium ions, and thrombocyte phospholipids converts prothrombin into thrombin. In intrinsic coagulation pathway FVIIIa/FIXa complex initiates blood coagulation by means of factor Xа generation. Activated factor Xа forms prothrombinase complex which provides the transformation of prothrombin into thrombin [Demetz and Ott 2012).

Thrombin carries out several functions. It contributes to the conversion of fibrinogen into soluble fibrin monomers. Thrombin transforms factor FXIII into factor FXIIIa, which binds fibrin monomers together. Thrombin activates factor XI which contributes to the generation of factor IXa active form by the alternative pathway (Butenas et al. 2003; Walsh 2003).

Recent studies demonstrated a role of tissue factor apart from hemostasis. Tissue factor plays a role in generation of coagulation proteases, and subsequent activation of protease activated receptors on vascular cells. This TF-mediated signaling leads to a number of biological processes like inflammation, angiogenesis, metastasis, and cell migration (Mackman 2009).

Tissue factor was incorrectly called thromboplastin. Thromboplastin was a lab reagent used to assay prothrombin time. Thromboplastin is the combination of both phospholipids and tissue factor, both needed in the activation of the extrinsic pathway of coagulation.

TF is expressed mainly on subendothelial tissues, but TF expression may be induced on endothelial cells by inflammatory mediators such as tumor necrosis factor (TNF-alpha). TF may also be found circulating on monocytes, on microparticles derived from various cellular sources, and in a soluble form arising from alternate processing of the TF gene. Subendothelial TF is responsible for initiating fibrin formation at sites of vascular injury; blood-borne TF may be an important contributor to propagation of the developing thrombus. Procoagulant activity of TF is regulated by tissue factor pathway inhibitor (TFPI) (Bajaj et al. 2001; Dennis et al. 2004).

In 1999, Giesen PL and colleagues examined thrombus formation on pig arterial media (which contained no stainable TF) and on collagen-coated glass slides (which were devoid of TF) by exposing them to flowing native human blood. In both the conditions, the thrombi stained intensely for TF, much of which was not associated with cells. Again antibodies against TF caused reduction in the amount of thrombus formed on both. A potent inhibitor of TF, factor VIIai, abolished fibrin production and markedly reduced the mass of the thrombi. They also revealed TF-positive membrane vesicles by immunoelectron microscopy. They measured TF by factor Xa formation from whole blood and plasma of healthy subjects. Immunostaining demonstrated TF-containing neutrophils and monocytes in peripheral blood. They concluded that leukocytes are the main source of blood-borne TF which is inherently thrombogenic and may be involved in thrombus propagation at the site of vascular injury (Giezen a, b).

The Role of Tissue Factor in Inflammation and Angiogenesis

Recent studies have shown that tissue factor takes part not only in hemostasis. Tissue factor is required for the formation of coagulation proteases and activation of their receptors on the vascular wall, which provokes intravascular thrombosis (Mackman 2004). Tissue factor modulates signal pathways for a number of biological processes, such as inflammation, angiogenesis, metastasis, and cell migration (Rickles et al. 2003; Mackman 2004; Steffel et al. 2006; Demetz and Ott 2012; Caterina 2015; Chu 2005, 2006, 2011). Tissue factor expression on the cells outside the vascular wall plays an essential role in hemostasis; on the other hand, its expression on endothelium induces intravascular thrombosis (Rickles et al. 2003; Borisoff et al. 2011).

Thrombocyte stimulation through protease receptors accelerates coagulation cascade. Most of these receptors are in the lipid anchors of stimulated thrombocytes. Lipid anchors are microdomains rich in cholesterol and sphingolipids, where membrane ligands localize and stimulation of cell signal pathways occurs (Baglia et al. 2003).

Thrombocytes accelerate coagulation cascade both by means of binding with factor XI through its glycoprotein receptor Ib-IX-V and by producing thrombogenic surface for prothrombinase complex.

There are four groups of receptors activated by thrombocytes (PAR). They are called PAR1, PAR2, PAR3, and PAR4. Each group of these receptors is activated by different proteases. Complex TF/FVIIa activates PAR2 (Camerer et al. 2000). Factor Xa activates both PAR1 and PAR2. Thrombin activates PAR1, PAR3, and PAR4. The study of keratinocytes and endothelial cells activated by cytokines has shown that PAR2 is directly influenced by complex TF/FVIIa and indirectly by factor X, whose active form is also generated by the complex described above (Mackman 2004). Basing on this evidence, it is suggested that PAR2 which are not activated by thrombin can act as sensors for coagulation proteases. This function contributes to endothelial activation in cases of damage or inflammation (Zhu et al. 2011). PAR represent a perfect mechanism providing the transfer of information about vascular wall mechanical injury to the cells (Zhu et al. 2011). Thus PAR participate in hemostasis, thrombosis, inflammation, and even in vascular wall formation.

PAR1, PAR2, and PAR4 are expressed in different cells of the vascular wall including endotheliocytes. The mediators of thrombin-mediated thrombocyte activation in a human are PAR1 and PAR4 (Coughlin 2000).

There are contradictory data about the integration into the cell membrane and release of tissue factor (Butenas et al. 2005). It was demonstrated that the integration was accompanied by posttranslational suppression of tissue factor procoagulant activity on the surface of the cell membrane (Butenas et al. 2004). In the bloodstream tissue factor is usually integrated into the cell membrane of thrombocytes and monocytes (Walsh 2003). In an undamaged cell tissue factor, procoagulant activity does not manifest itself anyway (Mackman 2004). The increase in ionized calcium content in cytosol can lead to the development of tissue factor procoagulant activity followed by activation of factor VII (Maly et al. 2003).

In 2006 C.E. Henriksson and co-workers established that ionized calcium increased intracellular activity of tissue factor but not of the tissue factor antigen on the surface of the cell membrane. This discrepancy between the activity of tissue factor itself and its antigen correlated with the increase in the number of cells containing phosphatidylserine, with most of them in necrotizing state and expressing tissue factor. The authors suggested that the dying cells containing tissue factor contributed to the discrepancy between the activity of tissue factor and its expression (Henriksson et al. 2007).

In 2008 J.J. Stampfuss and co-workers proposed that monocyte apoptosis resulted in significant increase of their procoagulant functions due to the tissue factor hyperexpression in cytoplasm and on the cell membrane.

Tissue factor is predominantly presented in subendothelium, but its expression on endothelial cells can be induced by such proinflammatory mediator as tumor necrosis factor-alpha (Kambas et al. 2008). Tissue factor can also be found on circulating monocytes, in microparticles produced by different cell surfaces, as well as in a soluble form resulting from the alternative way of genetic synthesis (Dietzen et al. 2004; Freeburn 1998). Subendothelial fraction of tissue factor is responsible for fibrin formation in damaged regions of vascular wall; the fraction circulating in blood significantly contributes to the thrombus formation (Bode and Mackman 2014). Procoagulant tissue factor activity is regulated by tissue factor inhibitor (Dietzen et al. 2004).

It has not been clear so far how tissue factor circulates; it can also be present in procoagulant microparticles.

In 2003 V.Y. Bogdanov and co-workers identified a tissue factor form synthesized by the alternative way. They found out that tissue factor synthesized by the alternative way predominantly contained extracellular domain but lacked transmembrane domain. Attachment of that tissue factor fraction to the thrombus surface provoked its further growth.

However the studies of P. Censarek and co-workers (2007) revealed that tissue factor synthesized by the alternative way did not have procoagulant activity. That tissue factor fraction was found to be associated with tumor cell proliferation and angiogenesis (Hobbs et al. 2007).

The contradiction in the assessment of tissue factor level in circulating blood results from the absence of reliable standards for its definition. Physiologically active tissue factor circulates in blood in concentrations over 30 pmoles both as corpuscle component and in the form of microparticles and as plasma protein as well (Butenas et al. 2005). However there has never been a description of a blood clot which would lack exogenous tissue factor. The addition of tissue factor to the whole blood in the amount of 16–20 fmoles was followed by the acceleration of blood clot formation. According to S. Butenas and colleagues, the concentration of physiologically active tissue factor not stimulated by cytokines does not exceed 20 fmoles in healthy people. The authors did not reveal any tissue factor or its antigen activity on native and ionophore-stimulated thrombocytes as well as on blood plasma mononuclear cells in the absence of stimulation, while the whole blood stimulated by lipopolysaccharide contained an essential fraction of monocytes expressing tissue factor. P.L. Giesen and colleagues in 1999 came to the conclusion that leukocytes were the main source of circulating in blood tissue factor involved into thrombus formation in vascular wall damaged regions.

In addition, tumor cells also express TF. It is now evident that tumor angiogenesis, metastasis, and invasiveness are highly dependent on components of the blood coagulation cascade. TF is known as a mediator of intracellular signaling events which can alter gene expression and cell behavior (Buzby et al. 2014). TF significantly participates in tumor-associated angiogenesis. Its expression has been correlated with the metastatic potential of many types of hematological malignancies (López-Pedrera et al. 2006).

Tissue Factor Involvement in Atherogenesis

Tissue factor plays an essential role in atherogenesis (Tremoli et al. 1999; Mackman 2004; Smith et al. 2005). Tissue factor is found in vascular adventitia and in lipid core of atherosclerotic plaque (Mackman 2004). Atherosclerotic plaque damage initiates coagulation due to the tissue factor flow from the lipid core to circulating blood (Wilcox et al. 1989). Tissue factor’s biologically active form is detected both in the vascular wall and circulating blood. It has been reported that TF intravascular fraction is increased in such prothrombotic syndromes as myocardial infarction, sepsis, and antiphospholipid syndrome (Tremoli et al. 1999; Moons et al. 2002; Rickles et al. 2003; Mackman 2004). Tissue factor expression increases in endothelial damage.

The term “vulnerable plaque” refers to the atherosclerotic plaque prone to rupture. At the site of plaque rupture, there is an accelerated entrance of its nucleus components, including tissue factor, into the circulating blood. This leads to the activation of coagulation cascade with the following thrombosis and vascular occlusion.

The term “vulnerable blood” refers to the blood predisposed to hypercoagulation. There are two different fractions of circulating tissue factor described. One of them is associated with the microparticles produced by cells in apoptosis, such as macrophages, smooth muscle cells, and endothelium. The other tissue factor fraction circulates in inactive form and, when activated, additionally reinforces thrombogenic potential (Mackman 2004).

Blood microparticles are vesicular structures with a diameter of 100–1,000 nm. They are present in the blood of normal subjects and in patients with various diseases. Microparticle membranes retain the protein receptors of their parent cells and may retain RNAs and other cytosolic content. On the basis of surface protein expression, microparticles are known to be derived from platelets, granulocytes, monocytes, endothelial cells, smooth muscle cells, and tumor cells. A subpopulation of these microparticles expresses tissue factor (Zwicker et al. 2011).

Human atherosclerotic plaques contain microparticles which are released during cell activation or apoptosis. Large amounts of microparticles are found in plaques but not in healthy vessels. Studies by Leroyer AS et al. have shown that microparticles are more abundant about 200 times and more thrombogenic in human atherosclerotic plaques than in plasma.

It has been established that TF initiates thrombogenic stimulus leading to the formation of a more stable thrombus. Tissue factor pool of plasma comprises TF associated with microparticles, its degradation products, and TF synthesized by the alternative way (Nieuland et al. 1997; Mackman 2004). Microparticles are lipid vesicles produced by thrombocytes, leukocytes, and endothelial cells (Ramacciotti et al. 2009; Zwiker et al. 2011).

Human atherosclerotic plaque contains microparticles which are produced during cell activation or their apoptosis (Stampfuss et al. 2008). A large number of microparticles was revealed in atherosclerotic plaques, but they were absent in healthy vessels (Drake et al. 1989). A.S. Leroyer and colleagues in 2007 reported that microparticles from atherosclerotic plaque were much more thrombogenic than microparticles of plasma. The microparticles in atherosclerotic plaque were mainly produced from leukocytes. In that study it was shown that microparticles both from atherosclerotic plaque and plasma contained tissue factor and generated thrombin, though that activity was twice higher in microparticles isolated from atherosclerotic plaques (Leroyer et al. 2007; Stojkovic 2014).

There was a study of tissue factor expression in smooth muscle cells of human coronary arteries. Tissue factor expression on the surface of smooth muscle cells was short-living, which limited thrombogenic potential of intact smooth muscle cells. On the other hand, intracellular pool is an additional source of TF. This may be meaningful in cases of smooth muscle cell damage, for instance, in atherosclerotic plaque erosion or in carrying out balloon angioplasty.

In myocardial infarction thrombocyte activation and endothelial apoptosis occur in response to the release of procoagulant microparticles from cell membranes into the blood stream (Morel et al. 2009). In patients with myocardial infarction and ST segment elevation, the levels of microparticles produced by leukocytes, endotheliocytes, and microparticles containing tissue factor were significantly higher in coronary artery occlusion zone, than in peripheral blood specimens (Morel et al. 2009). After coronary angioplasty and reestablished coronary blood flow, there was a significant reduction of procoagulant microparticles of leukocyte and endothelial origin (by 30% and 42%, correspondingly). Thus the increase of procoagulant microparticles in occluded coronary artery in patients with myocardial infarction associated with ST segment elevation seems to have a pathophysiologic role in coronary atherothrombosis (Morel et al. 2009).

It was determined that in patients who had undergone fibrinolysis for myocardial infarction with ST segment elevation, arterial recanalization in the infarct zone occurred in approximately 60% of cases (Huisse et al. 2009). There was an investigation of different hemostasis biomarkers in patient groups with myocardial infarction, who had not had recanalization after fibrinolysis. Unsuccessful fibrinolysis in myocardial infarction was characterized by a high procoagulant status due to the microparticles with tissue factor and low plasmin generation (Huisse et al. 2009).

In experimental trials it was reported that rapamycin intensified the activity of tissue factor and provoked arterial thrombosis in vivo in concentrations adequate to its content in drug-coated stents (Camici et al. 2010). The effect of second-generation drugs for drug-coated stents – everolimus and zotarolimus – was studied on the model of carotid artery photochemical damage of a mouse. Rapamycin, everolimus, and zotarolimus appeared to increase tissue factor expression, TNF alpha induced, by 2.2, 1.7, and 2.4 times, correspondingly, along with the increase of tissue factor superficial activity. These data should be taken into account in the construction of second-generation drug eluting stents (Camici et al. 2010).

B. Ray and colleagues in 2007 determined that in patients with intermittent claudication, tissue factor plasma concentration was significantly higher than in control group. The highest TF concentration was found in blood plasma of patients, who developed restenosis after iliofemoral angioplasty (Ray et al. 2007).

It is evident that proinflammatory mechanisms involved in atherosclerosis development can be accelerated under the influence of different factors, such as low-density lipoproteins, peroxidation products, activated blood cells, interleukins, interferon gamma, and CRP (Mallat et al. 1999; Ross 1999; von der Thüsen et al. 2003). It was found out that adipose tissue was functionally active and obesity predisposed to proinflammatory status (Libby 2002; Wang et al. 2010). The in vitro studies with resistin, recently described cytokine produced by adipose tissue, demonstrated that it induced proliferation of human coronary artery smooth muscle cells in dose-dependent degree by extracellular signal kinase and phosphatidylinositol kinase-3 activation (Calabroa et al. 2011). It was revealed that incubation with resistin induced tissue factor microRNA transcription and de novo functionally active TF synthesis. It was established that resistin-induced tissue factor activity in human endotheliocytes was enhanced by peroxidation products, and nuclear factor kappa B transcription potentially modulated that phenomenon (Calabroa et al. 2011).

J. Kim and colleagues in 2010 studied the pathogenetic role of receptor activator for nuclear factor ligand (RANKL) in advanced atherosclerosis (particularly, in atherosclerotic plaque rupture and destabilization). Polymerase chain reaction with reverse transcription and chromosomal analysis showed that RANKL elevated tissue factor microRNA level and procoagulant activity of macrophages (Kim et al. 2010).

One study demonstrated that interleukin-10 (IL-10) expression resulted in the suppression of tissue factor, IL-6, and TNF alpha synthesis (Baker et al. 2009).

Medicinal Correction of Tissue Factor Expression

Statins are the first-line drugs in carrying out secondary prevention of atherosclerosis in CAD patients (ГрацианскийН 1997). Simvastatin and ezetimibe effects on different parameters, including CRP and tissue factor level, were studied (Bruni et al. 2003). Both drugs improved lipid profile values and reduced CRP concentration; however they did not affect tissue factor and Willebrand factor levels (Kostakoua et al. 2010).

However another study investigated the effect of atorvastatin on tissue factor activity in thrombin-stimulated endotheliocytes, as well as the regulation of that activity by mevalonate and its derivatives (Martinez-Sales 2011). Tissue factor activity was assessed through its ability to induce factor Xa production. It was established that atorvastatin prevented thrombin-induced TF activation. Mevalonate and geranylgeranyl pyrophosphate reduced that inhibiting effect of atorvastatin on tissue factor activity, while farnesyl pyrophosphate did not produce such an effect (Martinez-Sales 2011).

Therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists contributed to the decrease of tissue factor level in patients with arterial hypertension (Soejima et al. 1999; Koh et al. 2004).

A new tendency in therapeutic strategy is the production of antibodies to tissue factor (Steffel et al. 2006).

Tissue Factor and the Risk of Coronary Artery Disease

In a number of clinical trials, it was revealed that tissue factor level in blood plasma was associated with the risk of acute coronary syndrome (Annex 1995; Suefuji et al. 1997; Misumi 1998; Falciani 1998) and myocardial infarction (Habis et al. 2000; Seljeflot et al. 2003; Campo et al. 2006; Morange et al. 2007; He et al. 2008). The increased level of tissue factor is the predictor of restenosis in CAD patients after angioplasty (Tutar et al. 2003).

There are several polymorphous variants of tissue factor gene (Arnaud et al. 2000; Opstad et al. 2010). A. Malarstig and colleagues in 2005 established that A5466G polymorphism of tissue factor gene was associated with the risk of cardiovascular death in patients with acute coronary syndrome (Malarstig 2005). In A allele carriers, there was revealed a threefold increase in the risk of fatal outcome. A. Evangelista and colleagues in 2015 did not find an association of TF A5466G polymorphism with venous and arterial thrombosis.

In G allele carriers of A603G polymorphism of tissue factor gene, there was an increased risk of myocardial infarction (Ott et al. 2004). It was in patients – G allele carriers – that a high concentration of tissue factor in blood plasma was found (Ott et al. 2004). In literature there are almost no clinical trials concerning the study of the abovementioned genotype association with the CAD onset age, myocardium, and vascular wall remodeling (Reny et al. 2004).

Thus tissue factor is not only the key element of atherothrombosis but also correlates with immunoinflammatory process and endothelium dysfunctions and has a prognostic value in patients with coronary artery disease.

Tissue Factor, Angiogenesis, and Myocardium Remodeling

In a number of studies, there was shown an association of tissue factor and its inhibitor with angiogenesis. Tissue factor physiological inhibitor suppresses endotheliocyte proliferation and tumor growth (Chen et al. 2001; Hembrough et al. 2004). Antiproliferative activity of tissue factor inhibitor is carried out through low-density lipoprotein receptors (Hembrough et al. 2004). It was determined that a special 23-amino acid fragment of tissue factor inhibitor molecule activated in contact with low-density lipoprotein receptor and showed antiangiogenic activity (Hembrough et al. 2003). Thus there may be a correlation between the molecular complex of tissue factor and its inhibitor in myocardium and proangiogenic mechanisms of myocardial hypertrophy development. The latter are also associated with intratissular renin-angiotensin system, which is a widely recognized trigger for cardiomyocyte hypertrophy. This is indirectly confirmed by the fact that angiotensin II receptor antagonists contribute to the reduction of tissue factor expression (Soejima et al. 1999; Koh et al. 2004) (Figs. 1, 2, and 3).
Tissue Factor, Fig. 1

Domain structure of tissue factor. Tissue factor is a transmembrane glycoprotein with the molecular weight of 47 kD which is fixed in the form of alpha-helix to a cell membrane. This protein consists of three domains and 263/261 amino acids. Extracellular domain is presented by NH2-terminal molecular part (amino acid residues from 1 to 219) and is made up of two fibronectin molecules of type III. There are three potential N-terminal binding areas with carbohydrates (Muller et al. 1994). Transmembrane hydrophobic domain by which tissue factor is fixed to the membrane (amino acid residues from 220 to 242). Cytoplasmic COOH-terminal domain. Amino acid sequences transcribed from nucleotide sequences of human placental DNA code have shown that tissue factor derives from a larger precursor molecule. The latter has an additiona l sequenceof 32 amino acids

Tissue Factor, Fig. 2

Tissue factor and extrinsic pathway of hemocoagulation. In extrinsic coagulation pathway tissue factor activates factor VII. Activated factor VII, in its turn, activates coagulation factors IX and X. Activated factor X in the presence of factor V, calcium ions and thrombocyte phospholipids converts prothrombin into thrombin. In intrinsic coagulation pathway FVIIIa: FIXa complex initiates blood coagulation by means of factor Xа generation. Activated factor Xа forms prothrombinase complex which provides the transformation of prothrombin into thrombin

Tissue Factor, Fig. 3

Tissue factor (TF) plays an important role at the crossroad of coagulation and inflammation, as the principal initiator of coagulation and an important modulator of inflammation. Proinflammatory cytokines can induce TF expression on mononuclear cells and endothelial cells and thereby commence pathways that lead to thrombin generation. Simultaneously, TF may bind to cellular receptors, which may affect the production and release of inflammatory mediators. TF bind to PAR2 receptor of macrophage and induce production of proinflammatory cytokines – IL-6, TNF-alpha. There is increasing experimental evidence that TF inhibition may have beneficial effects in disease states in which the combination of coagulation and inflammation plays a prominent role

References

  1. Annex BH, Denning SM, Channon KM. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91(3):619–22.PubMedCrossRefGoogle Scholar
  2. Arnaud E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, Arveiler D, Luc G, Ruidavets JB, Emmerich J. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l’Infarctus du Myocarde. Paris Thrombosis case-control Study. Arterioscler Thromb Vasc Biol. 2000;20:892–8.PubMedCrossRefGoogle Scholar
  3. Baglia AF, Shrimpton CN, Lopez JA, Walsh PN. The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane. J Biol Chem. 2003;278:21744–50.PubMedCrossRefGoogle Scholar
  4. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001;86:959–72.PubMedCrossRefGoogle Scholar
  5. Baker AK, WangR, Mackman N, Luyendyk JP. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Mol Immunol. 2009;46(11–12):2249–55.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Bode M, Mackman N. Regulation of tissue factor gene expression in monocytes and endothelial cells: thromboxane A2 as a new player. Vasc Pharmacol. 2014;62(2):57–62.CrossRefGoogle Scholar
  7. Borisoff JI, Spronk HM, Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364:1746–60.CrossRefGoogle Scholar
  8. Bruni F, Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Leo A, Auteri A. Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. Clin Exp Med. 2003;3(1):45–53.PubMedCrossRefGoogle Scholar
  9. Butenas S, Dee JD, Mann KG. The function of factor XI in tissue factor-initiated thrombin generation. J Thromb Hemostat. 2003;1(10):2103–11.CrossRefGoogle Scholar
  10. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood. 2005;105(7):2764–70.Google Scholar
  11. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation, which? where? when? Arterioscler Thromb Vasc Biol. 2009;29(12):1989–96.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Buzby J, Williams SA, Imfeld KL. Tissue factor inflammatory response regulated by promoter genotype and p 38 MAPK in neonatal vs. adult microvascular endothelial cells. Inflamm Res. 2014;63(4):299–308.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Calabroa P, Cirillob P, Limongellia G. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-ĸB-dependent pathway. J Vasc Res. 2011;48(1):59–66.CrossRefGoogle Scholar
  14. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. PNAS. 2000;97(10):5255–60.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Camici GG, Steffel J, Amanovic I, Breitenstein A, Baldinger J, Keller S, Lüscher TF, Tanner FC. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J. 2010;31(2):236–42.PubMedCrossRefGoogle Scholar
  16. Campo G, Valgimigli M, Ferraresi P. Tissue factor and coagulation factor VII levels during acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26(12):2800–6.PubMedCrossRefGoogle Scholar
  17. Caterina R. Inflammation and thrombosis. Proceedings of the ESC Congress; 2015.Google Scholar
  18. Chen C. C, Chen, N, Lau L. F. The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem. 2001;276, 13, 10443–52PubMedCrossRefGoogle Scholar
  19. Chu AJ. Tissue factor mediates inflammation. Arch Biochem Biophys. 2005;440(2):123–32.PubMedCrossRefGoogle Scholar
  20. Chu AJ. Role of tissue factor in thrombosis. Coagulation-inflammation-thrombosis circuit. Front Biosci. 2006;(11):256–71.Google Scholar
  21. Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflamm. 2011; 2011. Article ID. 367284. p 30.Google Scholar
  22. Coughlin SR. Thrombin signalling & protease activated receptors. Nature. 2000;407(6801):258–64.PubMedCrossRefGoogle Scholar
  23. Demetz G, Ott I. The interface between inflammation and coagulation in cardiovascular disease. Int J Inflamm. 2012. Article ID. 860301. p. 8.Google Scholar
  24. Dietzen DJ, Page KL, Tetzloff TA. Lipid rafts are necessary for tonic inhibition of cellular tissue factor procoagulant activity. Blood. 2004;103(8):3038–44.PubMedCrossRefGoogle Scholar
  25. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087–97.PubMedPubMedCentralGoogle Scholar
  26. Eddleston M, de la Torre JC, Oldstone MB. Astrocytes are the primary source of tissue factor in the murine central nervous system: a role for astrocytes in cerebral hemostasis. J Clin Invest. 1993;92(1):349–58.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Edgington TS, Mackman N, Brand K. The structural biology of expression and function of tissue factor. Thromb Haemost. 1991;66:67–79.PubMedPubMedCentralGoogle Scholar
  28. Evangelista FC, Rios DR, Ribeiro DD. Lack of association between potential prothrombotic genetic risk factors and arterial and venous thrombosis. Genet Mol Res. 2015;14(3):9585–94.PubMedCrossRefGoogle Scholar
  29. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost. 1998;79:495–9.PubMedCrossRefGoogle Scholar
  30. Fiore MM, Neuenschwander PF, Morrissey JH. The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa. J Biol Chem. 1994;269(1):143–9.PubMedPubMedCentralGoogle Scholar
  31. Fisher KL, Gorman CM, Vehar GA, O’Brien DP, Lawn RM. Cloning and expression of human tissue factor cDNA. Thromb Res. 1987;48:89–99.PubMedCrossRefGoogle Scholar
  32. Freeburn JC, Wallace JM, Strain JJ, Sinnamon DG, Craig BM, Johnson D, Gilmore WS. Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol. 1998;102:605–8.PubMedCrossRefGoogle Scholar
  33. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 1999a;96:2311–5.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Giesen PL, Rauch U, Bohrmann B. Blood-borne tissue factor: another view of thrombosis. PNAS. 1999b;96(5):2311–5.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Habis M, Gonzalez C, Jacq L, Pezzano M, Schaison F, Lardoux H. Hemostasis disturbances in myocardial ischemia. Ann Cardiol Angeiol. 2000;49(8):480–7.Google Scholar
  36. He WJ, Hu Y, Zhang XP, Hong M, Guo T, Wei WN, Song SJ. Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease. Eur J Med Res. 2008;13(2):47–51.PubMedPubMedCentralGoogle Scholar
  37. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003.;63(11):2997–3000.Google Scholar
  38. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood. 2004;103(9):3374–80.PubMedCrossRefGoogle Scholar
  39. Henriksson CE, Klingenberg O, Hellum M, Landsverk KS, Joø GB, Westvik AB, Kierulf P. Calcium ionophore-induced de-encryption of tissue factor in monocytes is associated with extensive cell death. Thromb Res. 2007;119(5):621–30.PubMedCrossRefGoogle Scholar
  40. Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, Crawford SE, Liu N, Signaevsky M, Soff GA. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res. 2007;120:S13–S21.PubMedCrossRefGoogle Scholar
  41. Huisse MG, Ajzenberg N, Feldman L, Guillin MC, Steg PG. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost. 2009;101:734–40.PubMedPubMedCentralGoogle Scholar
  42. Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, Deangelis RA, Lambris JD, Ritis KD. C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol. 2008;180(11):7368–75.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Kim J, Min JK, Park JA, et al. Receptor activator of nuclear factor kappa B ligand is a novel inducer of tissue factor in macrophages. J Circ Res. 2010;107(7):871–6.CrossRefGoogle Scholar
  44. Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH, Ahn TH, Choi IS, Shin EK. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis. 2004;177(1):155–60.PubMedCrossRefGoogle Scholar
  45. Kostakoua P, Kolovoua K, Anagnostopoulou K. Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand’s factor and C-reactive protein in patients with hypercholesterolaemia. Arch Cardiovasc Dis. 2010;103(1):26–32.CrossRefGoogle Scholar
  46. Lopez-Pedrera C, Barbarroja N, Dorado G, et al. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia. 2006;20(8):1331–40.PubMedCrossRefGoogle Scholar
  47. Mackman N. Regulation of the tissue factor gene. Thromb Haemost. 1997;78(1):747–54.PubMedPubMedCentralGoogle Scholar
  48. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arteriosclero Thromb Vasc Biol. 2004;24(6):1015–22.CrossRefGoogle Scholar
  49. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108(5):1447–52.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Mackman N, Parker JC. Tissue factor in the myocardium. Proceedings of the 18 Frontiers in Cardiovascullar Biology Congress; 2014.Google Scholar
  51. Malarstig A, Tenno T, Johnston N. Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes. Arterioscler Thromb Vasc Biol. 2005;25(12):2667–72.PubMedCrossRefGoogle Scholar
  52. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85(8):17–24.CrossRefGoogle Scholar
  53. Maly M, Vojacek J, Hrabos V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. Physiol Res. 2003;52:719–28.PubMedPubMedCentralGoogle Scholar
  54. Mariani G, Bernardi F, Bertina R. Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. Haematologica. 1999;84:620–6.PubMedPubMedCentralGoogle Scholar
  55. Martinez-Sales V, Vila V, Ferrando M, Reganon E. Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate. Cytotechnology. 2011;63(1):1–5.PubMedCrossRefGoogle Scholar
  56. Misumi K, Ogawa H, Yasue H, et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol. 1998;81(1):22–6.PubMedCrossRefGoogle Scholar
  57. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res. 2002;53(2):313–25.PubMedCrossRefGoogle Scholar
  58. Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Munzel T, Peetz D, Nicaud V. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost. 2007;5:475–82.PubMedCrossRefGoogle Scholar
  59. Morel O, Pereira B, Averous G. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: Role of endothelial damage and leukocyte activation. Atherosclerosis. 2009;204(2):636–41.PubMedCrossRefGoogle Scholar
  60. Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell. 1987;50:129–35.PubMedCrossRefGoogle Scholar
  61. Muller YA, Ultsch MH, Kelley RF, de Vos AM. Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry. 1994;33(36):10864–70.PubMedCrossRefGoogle Scholar
  62. Opstad TB, Pettersen AA, Weiss T. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J. 2010;8:7.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Ott I. Tissue factor in acute coronary syndromes. Semin Vasc Med. 2003;3:185–92.PubMedCrossRefGoogle Scholar
  64. Ott I, Koch W, von Beckerath N. Tissue factor promotor polymorphism-603 A/G is associated with myocardial infarction. Atherosclerosis. 2004;177(1):189–91.PubMedCrossRefGoogle Scholar
  65. Piazza L, Ridker PM. Is venous thromboembolism a chronic inflammatory disease? Clin Chem. 2015;61:313–6.PubMedCrossRefGoogle Scholar
  66. Ray B, Chetter IC, Lee HL, Ettelaie C, PT MC. Plasma tissue factor is a predictor for restenosis after femoropopliteal angioplasty. Br J Surg. 2007;94(9):1092–5.PubMedCrossRefGoogle Scholar
  67. Reny JL, Laurendeau I, Fontana P. The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thromb Haemost. 2004;91(2):248–54.PubMedPubMedCentralGoogle Scholar
  68. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124(3):58–68.CrossRefGoogle Scholar
  69. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340(2):115–26.PubMedCrossRefGoogle Scholar
  70. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid independent and dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991;266(4):2158–66.PubMedPubMedCentralGoogle Scholar
  71. Scarpati EM, Wen D, Broze GJ, Miletich JP, Flandermeyer RR, Siegel NR, Sadler JE. Human tissue factor: cDNA sequence and chromosome localizatopn of the gene. Biochemistry. 1987;26:5234–8.PubMedCrossRefGoogle Scholar
  72. Seljeflot I, Hurlen M, Hole T, Arnesen H. Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thromb Res. 2003;111:369–72.PubMedCrossRefGoogle Scholar
  73. Smith A, Hurlen M, Hole T, Arnesen H. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005;112(20):3080–7.PubMedCrossRefGoogle Scholar
  74. Soejima H, Ogawa H, Yasue H. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 1999;99(22):2908–13.PubMedCrossRefGoogle Scholar
  75. Spicer EK, Horton R, Bloem L. Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. PNAS. 1987;84(15):5148–52.PubMedPubMedCentralCrossRefGoogle Scholar
  76. Stampfuss JJ, Censarek P, Bein D. Membrane environment rather than tissue factor expression determines thrombin formation triggered by monocytic cells undergoing apoptosis. J Leukoc Biol. 2008;83(6):1379–81.PubMedCrossRefGoogle Scholar
  77. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113(5):722–31.PubMedCrossRefGoogle Scholar
  78. Stojkovic S. IL-33 induces tissue factor in human endothelial cells – impact on atherosclerotic plague thrombotic potential. Proceedings of the 18 Frontiers in Cardiovascullar Biology Congress; 2014.Google Scholar
  79. Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, Mizuno Y, Oshima S, Saito T, Tsuji I, Kumeda K, Kamikubo Y, Nakamura S. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J. 1997;134(2 Pt 1):253–9.PubMedCrossRefGoogle Scholar
  80. Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis. 1999;144(2):273–83.PubMedCrossRefGoogle Scholar
  81. von der Thüsen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 2003;55(1):133–66.PubMedCrossRefGoogle Scholar
  82. Walsh PN. Roles of factor XI, platelets and tissue factor-initiated blood coagulation. J Thromb Haemost. 2003;1(10):2081–6.PubMedCrossRefGoogle Scholar
  83. Wilcox JN, Smith KM, Schwartz SM, Gordon D, Wilcox JN. Localization of tissue factor in the normal vessel wall and the atherosclerotic plaque. Proc Natl Acad Sci. 1989;84(8):2839–43.CrossRefGoogle Scholar
  84. Zhu T, Mancini JA, Sapieha P, Yang C, Joyal JS, Honoré JC, Leduc M, Zaniolo K, Hardy P, Shao Z, Fan L, Hou X, Rivard GE, Chemtob S. Cortactin activation by FVIIa/tissue factor and PAR2 promotes endothelial cell migration. Am J Physiol Regul Integr Comp Physiol. 2011;300(3):R577–85.PubMedCrossRefGoogle Scholar
  85. Zwicker JI, Trenor CC, Furie BC, Furie B. Tissue factor-bearing microparticles and thrombus formation. Arterioscler. Thromb Vasc Biol. 2011;31(4):728–33.PubMedCrossRefGoogle Scholar
  86. Гpaциaнcкий HA. Hecтaбильнaя cтeнoкapдия – ocтpый кopoнapный cиндpoм. III. Пpeдупpeждeниe oбocтpeний ишeмичecкoй бoлeзни cepдцa. Cтaтины и aнтибиoтики. Кapдиoлoгия. 1997;37(11):4–17.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.I.P. Pavlov 1st Saint Petersburg State Medical UniversitySt. PetersburgRussia
  2. 2.Federal Almazov North-West Research CentreSt. PetersburgRussia